Dynamic fluorescence imaging approaches can be used to estimate the concentration of cell surface receptors in vivo. Kinetic models are used to generate the final estimation by taking the targeted imaging agent concentration as a function of time. However, tissue absorption and scattering properties cause the final readout signal to be on a different scale than the real fluorescent agent concentration. In paired-agent imaging approaches, simultaneous injection of a suitable control imaging agent with a targeted one can account for non-specific uptake and retention of the targeted agent. Additionally, the signal from the control agent can be a normalizing factor to correct for tissue optical property differences. In this study, the kinetic model used for paired-agent imaging analysis (i.e., simplified reference tissue model) is modified and tested in simulation and experimental data in a way that accounts for the scaling correction within the kinetic model fit to the data to ultimately extract an estimate of the targeted biomarker concentration.
INTRODUCTION
In cancer therapy, characterizing different types of biomarkers is a key component in identifying patients who are likely to respond to a given therapy. 1 Moving away from measuring these biomarkers from tumor biopsies and toward more non-invasive methods such as imaging techniques should allow better monitoring of oncology patients. 2, 3 In fluorescence imaging, syntheses of new targeted imaging agents are rapidly expanding. 4, 5 Despite its limitations in whole-body human imaging, fluorescence imaging is suitable for dynamic small animal "in vivo" imaging. 6, 7 Cell surface receptors that transmit proliferation signals are important biomarkers in cancer research. 8, 9 Mathematical models are needed to analyze the fluorescence data and to quantify the available cell surface receptors. [10] [11] [12] [13] [14] Paired-agent imaging is a successful approach to quantify cell surface receptors in vivo. 15, 16 In this technique, a second control counterpart of the targeted imaging agent is co-injected with the targeted one to account for non-specific uptake and retention of the targeted imaging agent. 17, 18 The control agent is labeled with fluorophore having its emission peak at a different channel than the targeted fluorophore. In this way, the two imaging agents can be imaged at the same time with a spectrally resolved imaging device. Paired-agent imaging has shown promising results in quantifying cell surface receptors. 19, 20 However, distorting effects of the optical absorption and scattering of tissue is an obstacle in measuring of fluorescent agent concentrations accurately. 21 These tissue optical property effects could cause errors in paired-agent imaging, if not accounted for, since the two imaging agents are often imaged at different wavelength that could have different tissue optical properties. As a result, a normalization tool must be applied to correct for tissue optical property differences. In the previous study, 22 a pixel-by-pixel normalization tool was demonstrated to partially account for spatial variability in the optical property differences by dividing the targeted signal to the control signal at In this method it is assumed that an early time point data after injection is available and the targeted and control signals are affected only by the tissue optical properties at early time points after imaging agent administration. 22 Correcting for optical tissue properties with a factor in the kinetic model is another way of normalizing for tissue attenuation between the two imaging agents. In this study, the dynamic simplified reference tissue kinetic model that is applied to the paired-agent imaging methods is compared in two different cases: 1) as it was originally used by taking the pixel-by-pixel normalized targeted and control curves for its inputs and 2) as a modified version by taking the intact signals directly to the model. The models were evaluated in simulation and in a subcutaneous tumor mouse study.
METHODS AND RESULTS

Animal Experiment
The detailed animal model study can be found here. 23 Briefly, a group (n = 6) of athymic nude mice were injected subcutaneously with A431 tumor, known for a high level of epidermal growth factor receptor (EGFR) overexpression. After the tumors got to the appropriate size (about 5 mm in diameter), the skin above the tumors was removed, and the mice were injected intravenously with a cocktail of IRDye 800CW-EGF (targeted) and IRDye 700DX-carboxylate (control) (0.2 nanomoles each). Mice were immediately placed in a two-channel (700 and 800 nm) Odyssey (LICOR Biosciences, Lincoln, NE) scanner and fluorescent images at 700-740 nm (excitation: 685 nm) and 800-840 nm (excitation: 785 nm) were acquired every two minutes for 1 h. The data were later corrected by normalizing each image stack with a pixel-by-pixel normalization factor (the details of this approach can be found in 22 ). The corrected data were evaluated by the original simplified reference tissue model (O-SRTM) explained in 2.3.1. Moreover, the raw data were given inputed to the modified SRTM (M-SRTM) as explained in section 2.3.2. . In all of this, it is assumed the uptake of the two imaging agents are similar in the blood plasma, however, this assumption needs to be tested in future work. 24 
Simulation
A simulation study was carried out by creating targeted and control imaging agent concentration curves from an experimentally-derived plasma input curve of EGF molecule. The data is solved through a standard Kety model. 25 After giving artificial scales to the targeted curves (to simulate the scale differences), the created curves were given 1000 times noise iterations and they were fitted into the O-SRTM and M-SRTM. Figure 2 Scaling Factor (a) Scaling Factor (a)
normalization from 1 minutes to 10 minutes post tracers injection. According to this plot the underestimaton of BP increases by increasing the pixel-by-pixel normalization time. In Figure 3 , the results of O-SRTM and M-SRTM parameter estimation, for different given scaling factors are shown. According to this figure, both models are pretty stable in BP estimation regardless of the given scaling factor. O-SRTM is underestimating the BP for about 2.5% and M-SRTM is overestimating it for about 5%. The underestimation of BP by O-SRTM will increase by increasing the time of normalization from 1 minute post-injection. O-SRTM underestimates the k 2 and R 1 parameters while M-SRTM overestimate the k 2 and underestimate α. 
Paired-agent Kinetic Model
Paired-agent kinetic models are based on a two-tissue and one-tissue compartment models. Schematic details of the model is shown in Figure 4 . The goal of the model is to estimate the binding potential (BP), a parameter proportional to cell surface receptor concentration. Figure 4 . On the left is a schematic of subcutaneous mouse tumor model is represented. In the middle is an illustration of single targeted imaging agent (top) and how non-specific retention can happen on the surface of a cell or in free space, and the paired-agent imaging methods (bottom) and how it is accounted for the non-specific uptake by a control imaging agent is shown. On the right, compartment models for both the targeted and control tracers are depicted on top and bottom, respectively. K1 and k2 represent transit rates of the tracers from the blood plasma, to the extravascular space and back; k3 and k4 represent association and dissociation rates of the targeted tracers. Binding potential (BP), is a parameter proportional to the receptor concentration (B avail ). KD is the dissociation rate constant that relates the BP to B avail .
Original Reference Tissue Model (O-SRTM)
Quantification of EGFR was determined using a least square curve fit model in Matlab R2016a. The kinetic model is developed and adopted from a simplified reference tissue model originally introduced for PET imaging.
26
The model is shown in equation (1)
where, ROI T and ROI C are detected targeted and control agent signals measured in a region of interest, respectively. η T and η C are correction factors relating detected targeted and control agent signals to corresponding agent concentration. R 1 is the ratio of extravasation of the targeted to the control agent. k 2 is the efflux rate constant, BP is the binding potential, t is the time and * is convolution. In pixel-by-pixel paired-agent imaging approaches, the η T /η C ratio was considered to be 1. As a result, the final number of fitting parameters in O-SRTM is reduced to 3 parameters R 1 , k 2 , and BP.
Modified Reference Tissue Model (M-SRTM)
The modified SRTM, M-SRTM, is introduced in equation (2) . In this model the new parameter of α tumor is introduce to the model for the η T η C . This means a new fitting parameter is added to the model, however, by keeping R 1 close to 1, by choosing imaging agents that have similar rate of extravasation from blood flow, as a result, the final fitting parameters are α tumor , k 2 and BP.
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